Addendum

Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110

Status
Status: Commission completed
Project no.
A24-34
Last updated

Report documents

  1. Addendum

    Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110

    published on
    Document type
    PDF document, 339 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-34_en

Dossier assessment

Indication:

In combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia who are FMS-like tyrosine kinase 3 mutation-positive

Result of dossier assessment:

Unchanged after addendum: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2024-05-02 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A24-34
Commission
Commission awarded on 27.03.2024 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A24-34_en

Connected Projects

  1. Dossier assessment

    Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-110
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form